



Contacts:

Idera Pharmaceuticals, Inc.  
617-679-5500, x5517  
Robert G. Andersen  
E-mail: randers@iderapharma.com

MacDougall Biomedical  
Communications  
508-647-0209 x12  
Douglas MacDougall

**IDERA PHARMACEUTICALS TO PARTICIPATE IN FOCUS SESSION AT BIO CEO  
& INVESTOR CONFERENCE**

**Cambridge MA, February 13, 2006** – Idera Pharmaceuticals, Inc. (AMEX: IDP) announced today that Sudhir Agrawal, D. Phil., Idera’s Chief Executive Officer and Chief Scientific Officer will participate in a Drug Development Focus Session at the BIO CEO & Investor Conference 2006, taking place at the Waldorf Astoria Hotel in New York City February 13<sup>th</sup> through February 15<sup>th</sup>.

The session, entitled, “Toll-Like Receptors: The Cure for All Ailments?” will take place at 8:30 am ET on Wednesday, February 15<sup>th</sup> in the Basildon Room.

Toll-like receptors (TLRs) function in immune cells as the sensors of pathogens. They recognize different molecules present in pathogens, such as bacteria, viruses and parasites, and mount an appropriate immune response against the foreign invaders. TLRs have become attractive targets for developing immune modulators to treat a number of diseases including cancer, asthma, allergies, and infectious diseases.

For more information on the session or the conference, please visit:  
<http://ceo.bio.org/opencms/ceo/2006/program/index.jsp>.

**About Idera Pharmaceuticals, Inc.**

Idera Pharmaceuticals, Inc. (AMEX: IDP) is a Cambridge, Massachusetts-based biotechnology company focused on the discovery, development, and commercialization of targeted immune therapies based on modulation of Toll-like receptors (TLRs), a class of receptors with broad commercial potential in the areas of oncology, infectious disease and allergy/asthma. Idera’s most advanced clinical candidate, IMO2055 (or HYB2055), targets TLR9 and is currently in a Phase 2 monotherapy trial in renal cell carcinoma, and a Phase 1/2 combination therapy trial in non-small-cell lung cancer. Idera is collaborating with Novartis on drug candidates targeting asthma and allergies and has identified pre-clinical candidates in-house targeting a variety of infectious diseases. For more information, visit [www.iderapharma.com](http://www.iderapharma.com).

###